Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Acquisitions: 2020-2021

Historic Acquisitions for Anika Therapeutics (ANIK) over the last 2 years, with Dec 2021 value amounting to $113,000.

  • Anika Therapeutics' Acquisitions fell 84.77% to $113,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $476,000, marking a year-over-year change of. This contributed to the annual value of $476,000 for FY2021, which is 99.50% down from last year.
  • Anika Therapeutics' Acquisitions amounted to $113,000 in Q4 2021, which was up 927.27% from $11,000 recorded in Q3 2021.
  • Over the past 5 years, Anika Therapeutics' Acquisitions peaked at $93.0 million during Q1 2020, and registered a low of $2,000 during Q2 2021.
  • Its 2-year average for Acquisitions is $13.6 million, with a median of $350,000 in 2021.
  • Data for Anika Therapeutics' Acquisitions shows a maximum YoY tumbled of 99.77% (in 2021) over the last 5 years.
  • Over the past 2 years, Anika Therapeutics' Acquisitions (Quarterly) stood at $742,000 in 2020, then crashed by 84.77% to $113,000 in 2021.
  • Its last three reported values are $113,000 in Q4 2021, $11,000 for Q3 2021, and $2,000 during Q2 2021.